Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, the measurement of blood pressure, and the collection of blood samples. The company also offers interventional products, including various coronary catheters, structural heart support devices, peripheral intervention products, and mechanical circulatory support platform; and Arrow branded intra-aortic balloon pumps and catheters, Guideliner, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway, pain management, and hemostatic products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligating clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology, as well as bladder management services; and OEM products, which includes the TFX Medical OEM, TFX OEM, Deknatel, and HPC Medical brands. It serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Analyst Outlook | Price targets range from $210 to $285, reflecting varied optimism about Teleflex's future prospects and ability to overcome current headwinds |
Strategic Vision | Delve into Teleflex's growth strategy, combining organic expansion with strategic acquisitions to strengthen market position and drive innovation |
Market Dynamics | Explore Teleflex's navigation of complex market forces, from unexpected customer losses to promising growth in key segments like Intra-Aortic Balloon Pumps |
Financial Resilience | Teleflex demonstrates adaptability amidst challenges, adjusting guidance while maintaining profitability through effective cost management and strategic initiatives |
Metrics to compare | TFX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTFXPeersSector | |
---|---|---|---|---|
P/E Ratio | 38.2x | 35.1x | −0.5x | |
PEG Ratio | −0.78 | 0.15 | 0.00 | |
Price / Book | 1.4x | 4.1x | 2.6x | |
Price / LTM Sales | 1.9x | 7.0x | 2.9x | |
Upside (Analyst Target) | 12.9% | 19.8% | 45.8% | |
Fair Value Upside | Unlock | −15.3% | 8.6% | Unlock |